This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Melero, I. Articles by Prieto, J. Search for Related Content PubMed PubMed Citation Articles by Melero, I. Articles by Prieto, J.

An Anti-ICAM-2 (CD102) Monoclonal Antibody Induces Immune-mediated Regressions of Transplanted ICAM-2-negative Colon Carcinomas¹

Gene Therapy Unit, Department of Medicine, University of Navarra School of Medicine, 31008 Pamplona [I. M., I. G., G. M., V. S., M. R-C., I. T., J. P.]; Proteomics Facility and Department of Immunology and Oncology, Centro Nacional de Biotecnología (Pharmacia/ Consejo Superior de Investigaciones Cientificas), Canto Blanco, E-28049 Madrid [E. C., J. P. A.]; and Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Cientificas, 28006 Madrid [A. L. C., M. R.] Spain

Monoclonal antibodies (mAbs) can mediate antitumor effects by indirect mechanisms involving antiangiogenesis and up-regulation of the cellular immune response rather than by direct tumor cell destruction. From mAbs raised by immunization of rats with transformed murine endothelial cells, a mAb (EOL4G8) was selected for its ability to eradicate a fraction of established colon carcinomas that did not express the EOL4G8-recognized antigen. The antigen was found to be ICAM-2 (CD102). Antitumor effects of EOL4G8, which required a functional T-cell compartment, were abrogated by depletion of CD8⁺ cells and correlated with antitumor CTL activity, whereas only a mild inhibition of angiogenesis was observed. Interestingly, we found that EOL4G8 acting on endothelial ICAM-2 markedly enhances leukotactic factor activity-1-independent adhesion of immature dendritic cells to endothelium—an effect that is at least in part mediated by DC-SIGN (CD209).

This article has been cited by other articles:

				O. Murillo, A. Arina, S. Hervas-Stubbs, A. Gupta, B. McCluskey, J. Dubrot, A. Palazon, A. Azpilikueta, M. C. Ochoa, C. Alfaro, et al. Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma Clin. Cancer Res., November 1, 2008; 14(21): 6895 - 6906. [Abstract] [Full Text] [PDF]

				M.-T. Huang, J. C. Mason, G. M. Birdsey, V. Amsellem, N. Gerwin, D. O. Haskard, A. J. Ridley, and A. M. Randi Endothelial intercellular adhesion molecule (ICAM)-2 regulates angiogenesis Blood, September 1, 2005; 106(5): 1636 - 1643. [Abstract] [Full Text] [PDF]

				N. Kilic, L. Oliveira-Ferrer, J.-H. Wurmbach, S. Loges, F. Chalajour, S. N. Vahid, J. Weil, M. Fernando, and S. Ergun Pro-angiogenic Signaling by the Endothelial Presence of CEACAM1 J. Biol. Chem., January 21, 2005; 280(3): 2361 - 2369. [Abstract] [Full Text] [PDF]

				O. Murillo, A. Arina, I. Tirapu, C. Alfaro, G. Mazzolini, B. Palencia, A. L.-D. De Cerio, J. Prieto, M. Bendandi, and I. Melero Potentiation of Therapeutic Immune Responses against Malignancies with Monoclonal Antibodies Clin. Cancer Res., November 15, 2003; 9(15): 5454 - 5464. [Abstract] [Full Text] [PDF]

				I. Melero, I. Gabari, I. Tirapu, A. Arina, G. Mazzolini, E. Baixeras, E. Feijoo, C. Alfaro, C. Qian, and J. Prieto Anti-ICAM-2 Monoclonal Antibody Synergizes with Intratumor Gene Transfer of Interleukin-12 Inhibiting Activation-induced T-Cell Death Clin. Cancer Res., September 1, 2003; 9(10): 3546 - 3554. [Abstract] [Full Text] [PDF]